Results 81 to 90 of about 21,298 (206)

Predictive Role of Serum Inflammatory Markers in Metastatic Luminal A/B Breast Cancers Receiving CDK‐4/6 Inhibitors Therapy

Immunity, Inflammation and Disease, Volume 14, Issue 4, April 2026.
ABSTRACT Background We conducted this study to evaluate the impact of serum inflammatory markers and histopathological features on prognosis in metastatic hormone receptor positive breast cancer patients treated with first line CDK4/6i (cyclin‐dependent kinase inhibitors).
Nilufer Bulut, Tanju Kapagan, Aykut Ozmen, Gokmen Umut Erdem   +3 more
wiley   +1 more source

Long Non-Coding RNA H19 Acts as an Estrogen Receptor Modulator that is Required for Endocrine Therapy Resistance in ER+ Breast Cancer Cells

Cellular Physiology and Biochemistry, 2018
Background/Aims: Blocking estrogen signaling with endocrine therapies (Tamoxifen or Fulverstrant) is an effective treatment for Estrogen Receptor-α positive (ER+) breast cancer tumours.
Pratima Basak, Sumanta Chatterjee, Vasudeva Bhat, Alice Su, Hyerang Jin, Victoria Lee-Wing, Qian Liu, Pingzhao Hu, Leigh C Murphy, Afshin Raouf   +9 more
doaj   +1 more source

Involvement of miR-106b in tumorigenic actions of both prolactin and estradiol. [PDF]

, 2017
Prolactin promotes a variety of cancers by an array of different mechanisms. Here, we have investigated prolactin's inhibitory effect on expression of the cell cycle-regulating protein, p21.
Bustamante, Karissa, Chen, Kuan-Hui Ethan, Nguyen, Vi, Walker, Ameae M   +3 more
core   +1 more source

Optimizing the integration of modern systemic therapies and advanced radiotherapy techniques in breast cancer management: An expert opinion from the Institut Curie Breast Radiotherapy Group

International Journal of Cancer, Volume 158, Issue 7, Page 1775-1784, 1 April 2026.
Abstract The integration of modern systemic therapies with radiotherapy (RT) represents a promising strategy in breast cancer management, enhancing both locoregional control and systemic disease outcomes. This expert consensus from the Institut Curie Breast Radiotherapy Group focuses exclusively on modern systemic agents, synthesizing current evidence ...
Cezara Cheptea, Pierre Loap, Sofiane Allali, Alain Fourquet, Kim Cao, Youlia Kirova   +5 more
wiley   +1 more source

Palbociclib has no clinically relevant effect on the QTc interval in patients with advanced breast cancer. [PDF]

, 2018
The aim of this study was to assess the potential effects of palbociclib in combination with letrozole on QTc. PALOMA-2, a phase 3, randomized, double-blind, placebo-controlled trial, compared palbociclib plus letrozole with placebo plus letrozole in ...
Durairaj, Chandrasekar, Ettl, Johannes, Finn, Richard S, Gauthier, Eric R, Hoffman, Justin T, Huang, Xin, Joy, Anil A, Lu, Dongrui R, Rugo, Hope S, Ruiz-Garcia, Ana, Wang, Diane D, Wilner, Keith D, Zheng, Jenny   +12 more
core   +2 more sources

Grade 3 Hepatotoxicity following Fulvestrant, Palbociclib, and Erdafitinib Therapy in a Patient with ER-Positive/PR-Negative/HER2-Negative Metastatic Breast Cancer: A Case Report

Case Reports in Oncology, 2020
A 49-year-old woman with ER-positive/PR-negative/HER2-negative metastatic breast cancer experienced Grade 3 hepatotoxicity following initiation of a clinical trial of fulvestrant, palbociclib, and erdafitinib.
Alyssa Schlotman, Adam Stater, Kyle Schuler, Judd Heideman, Vandana Abramson   +4 more
doaj   +1 more source

The pituitary TGFb1 system as a novel target for the treatment of resistant prolactinomas [PDF]

, 2016
Prolactinomas are the most frequently observed pituitary adenomas and most of themrespond well to conventional treatment with dopamine agonists (DAs).
Camilletti, María Andrea, Diaz, Graciela Susana, Recouvreux, Maria Victoria, Rifkin, Daniel B.   +3 more
core   +2 more sources

The use of fulvestrant, a parenteral endocrine agent, in intestinal obstruction due to metastatic lobular breast carcinoma

World Journal of Surgical Oncology, 2008
Background The role of fulvestrant in the management of intestinal obstruction associated with lobular carcinoma has not been specifically described.
Rampaul Rajendra Singh, Tang Jasmine YM, Cheung Kwok L   +2 more
doaj   +1 more source

Palbociclib plus letrozole as first-line therapy in estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer with extended follow-up. [PDF]

, 2019
PurposeIn the initial PALOMA-2 (NCT01740427) analysis with median follow-up of 23 months, palbociclib plus letrozole significantly prolonged progression-free survival (PFS) in women with estrogen receptor-positive (ER+)/human epidermal growth factor ...
Bartlett, C Huang, Castrellon, A, Diéras, V, Ettl, J, Finn, RS, Gauthier, ER, Gelmon, KA, Harbeck, N, Iyer, S, Joy, AA, Lipatov, O, Lu, DR, Mori, A, Rugo, HS, Slamon, DJ   +14 more
core  

The MPA mouse breast cancer model: evidence for a role of progesterone receptors in breast cancer [PDF]

, 2009
More than 60% of all breast neoplasias are ductal carcinomas expressing estrogen (ER) and progesterone receptors (PR). In contrast, most of the spontaneous, chemically or MMTV induced tumors, as well as tumors arising in genetically modified mice do not ...
Bottino, Maria Cecilia, Cerliani, Juan Pablo, Fabris, Victoria Teresa, Giulianelli, Sebastian Jesus, Helguero, Luisa A., Lamb, Caroline Ana, Lanari, Claudia Lee Malvina, Molinolo, Alfredo, Soldati, Rocío, Wargon, Victoria   +9 more
core   +1 more source